3. Pharmaceutical firms also conduct research to assess the efficiency of a treatment program. Suppose a new anti-viral drug for COVID-19 is currently under investigation, this is given to patients...

Extracted text: 3. Pharmaceutical firms also conduct research to assess the efficiency of a treatment program. Suppose a new anti-viral drug for COVID-19 is currently under investigation, this is given to patients after the signs of COVID-19 have become evident. The overall amount of time in months that patients begin to stay aftercare is of concern. There are two researcher, each of whom follows a different set of 40 COVID-19 patients from the beginning of treatment through to death. Each researcher collects the following data (in months). Researcher 1: 3: 4; 10; 15; 16; 17; 22; 44; 37; 16; 14; 24; 25; 15; 26; 27; 33; 30; 35; 44; 13; 21; 21; 10; 12; 8; 40; 32; 26; 27; 33; 34; 29; 17; 8; 24; 19; 47; 33; 34 Researcher 2: 3; 14; 15; 5; 16; 17; 28; 40; 30; 18; 14; 14; 26; 25; 21; 22; 31; 2; 35; 44; 23; 22; 22; 21; 16; 12; 18; 41; 22; 16; 27; 33; 34; 29; 13; 18; 24; 24; 42; 33; 29 2. Define the key terms based on the above given for Researcher 1. a. Sample b. Population I C. Data d. Variable